Drugs / [Ac-225]-PSMA-62
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06229366 | Apr 2024 → Sep 2027 expected | prostate carcinoma | Eli Lilly and Company | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [Ac-225]-PSMA-62 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06229366 ↗ |
| Route | Intravenous | “Administered intravenously” NCT06229366 ↗ |